Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

The possibility that the high frequency of treatment failures in Indian kala-azar might be due to infection with antimony-resistant strains of Leishmania donovani has not been experimentally addressed. L. donovani isolates were obtained from splenic aspiration smears of 24 patients in Bihar, India, who either did not respond (15) or did respond (9) to 1 or more full courses of treatment with sodium antimony gluconate (SAG). A strong correlation (P<.001) between clinical response and SAG sensitivity in vitro was observed only when strains were assayed as intracellular amastigotes: responsive isolates ED50=2.4+/-2.6, ED90=6.4+/-7.8 microgram SAG/mL; unresponsive isolates ED50=7.4+/-3.7 microgram SAG/mL, ED90=29.1+/-11.1 SAG/mL. No correlation with clinical response was found by use of extracellular promastigotes (ED50=48+/-22 vs. 52+/-29 microgram/mL). The emergence of antimony-resistant L. donovani strains appears to be a cause of treatment failures in India.

[1]  A. Pandey,et al.  Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases , 1998 .

[2]  S. Sundar,et al.  Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis , 1997 .

[3]  E. Waldman,et al.  Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes , 1997, Antimicrobial agents and chemotherapy.

[4]  R. Piarroux,et al.  In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis , 1997, Antimicrobial agents and chemotherapy.

[5]  J. Berman,et al.  In vitro antileishmanial properties of tri- and pentavalent antimonial preparations , 1995, Antimicrobial agents and chemotherapy.

[6]  U. Biswas,et al.  Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar , 1994, The Lancet.

[7]  M. Grogl,et al.  Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. , 1992, The American journal of tropical medicine and hygiene.

[8]  S. Reed,et al.  Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. , 1990, The American journal of tropical medicine and hygiene.

[9]  C. P. Thakur,et al.  Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study , 1988, British medical journal.

[10]  J. Berman,et al.  Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. , 1984, The Journal of parasitology.

[11]  C. P. Thakur,et al.  Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. , 1998, Annals of tropical medicine and parasitology.

[12]  S. Sundar.  TREATMENT OF VISCERAL LEISHMANIASIS : CURRENT STATUS , 1997 .

[13]  M. Ouellette,et al.  New mechanisms of drug resistance in parasitic protozoa. , 1995, Annual review of microbiology.

[14]  Thakur Cp.  Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis) , 1984 .